Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP TEENS Weight Maintenance
2023-508055-40-00Phase 4Authorised
- Sponsor
- Novo Nordisk
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 13
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in obesity, sponsored by Novo Nordisk. Primary endpoint: Maintenance of BMI below obesity threshold. Planned start Feb 2025; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2023-508055-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508055-40-00.